Many people who recover from COVID-19 find themselves dealing with something unexpected: pain that lingers for weeks, months, or even longer after the infection has cleared. This is not imagination, and it is not weakness. Scientists and doctors have identified real, measurable biological reasons why COVID-19 can trigger persistent pain in some individuals.
This article explains exactly what is happening inside the body when post-COVID pain develops. It covers how the virus interacts with the nervous system, why inflammation plays such a central role, what “long COVID” pain actually looks like in practice, and how the body attempts to manage these signals over time. It also looks at what current research is uncovering about treatment and recovery.
Whether you are personally affected or simply want to understand this better, the explanations here are grounded in science and written to be genuinely clear.
How COVID-19 Causes Persistent Pain
COVID-19 does not always leave the body after the initial infection clears. For many people, pain continues for weeks or months afterward. Scientists have identified several biological reasons why this happens, and understanding them helps explain why recovery can feel so frustratingly slow.
Key Pain Mechanisms
The following mechanisms explain the main biological pathways through which COVID-19 produces persistent pain.
- Central Sensitization occurs when the nervous system becomes overly sensitive after an infection. The brain and spinal cord essentially get “stuck” in alarm mode, amplifying pain signals even when no new injury exists. This produces widespread body aches, heightened sensitivity to touch, and pain that seems disproportionate to any obvious physical cause.
- Neuroinflammation means inflammation occurring inside the brain and nervous system itself. COVID-19 can trigger immune responses that damage or irritate nerve tissue directly, leading to headaches, brain fog, and burning or shooting pain throughout the body.
- Residual Musculoskeletal Inflammation refers to lingering inflammation in muscles, joints, and connective tissue after the virus has gone. The immune system sometimes continues producing inflammatory chemicals long after the threat has passed, causing joint stiffness, muscle soreness, and deep body aches.
- Small Fiber Neuropathy involves damage to tiny nerve fibers found just beneath the skin. When COVID-19 injures these fibers, people experience burning sensations, numbness, and tingling, particularly in the hands and feet.
- Mast Cell Dysregulation involves immune cells called mast cells becoming overactive. These cells normally help fight infection, but when dysregulated, they release chemicals that cause widespread inflammation, skin sensitivity, and pain flares triggered by ordinary activities or even foods.
Together, these five mechanisms illustrate the diverse and overlapping biological pathways through which COVID-19 can produce persistent pain.
Pain Mechanism Overview
The table below summarizes each pain mechanism, its plain-language explanation, and the symptoms it produces.
| Mechanism | Plain-Language Explanation | Symptoms It Produces |
|---|---|---|
| Central Sensitization | Nervous system stays stuck in “high alert,” magnifying pain signals | Widespread aches, touch sensitivity, disproportionate pain |
| Neuroinflammation | Inflammation damages or irritates brain and nerve tissue | Headaches, brain fog, burning or shooting nerve pain |
| Residual Musculoskeletal Inflammation | Immune chemicals keep attacking muscles and joints after infection ends | Joint stiffness, muscle soreness, deep body aches |
| Small Fiber Neuropathy | Tiny skin-level nerve fibers are physically damaged by the virus | Burning, numbness, tingling in hands and feet |
| Mast Cell Dysregulation | Overactive immune cells flood the body with inflammatory chemicals | Skin sensitivity, pain flares, widespread inflammation |
This overview highlights how each mechanism contributes to a distinct but often overlapping pattern of post-COVID symptoms.
The Body’s Own Pain-Management System
Your body does not simply experience pain and leave it at that. It has a built-in system designed to regulate, dampen, and manage pain signals before they become overwhelming. One of the most important of these systems is the endocannabinoid system, or ECS. Think of it as your body’s internal volume control for pain — it can turn the signal up or down depending on what the situation demands.
The ECS works through two main types of receptors found throughout the body. CB1 receptors are located primarily in the brain and spinal cord, where they help regulate how pain signals are interpreted and processed centrally. When something hurts, CB1 receptors help determine how intensely that pain registers in your awareness. CB2 receptors, on the other hand, are found mainly in immune cells and peripheral tissues — meaning areas outside the brain. Their primary job involves managing inflammation, which is one of the root drivers of pain in the first place.
Together, these two receptor types form a finely balanced network. When the ECS functions properly, pain is processed accurately and inflammation is kept in check.
In post-COVID patients, however, growing evidence suggests this system becomes disrupted. COVID-19 triggers intense immune responses that may interfere with ECS signaling, leaving CB1 and CB2 receptors less effective than normal.
ECS Functioning Normally vs. ECS Disrupted by COVID-19
The table below compares how the endocannabinoid system operates under normal conditions versus when it has been disrupted by COVID-19.
| Feature | ECS Functioning Normally | ECS Disrupted by COVID-19 |
|---|---|---|
| Pain signal processing | Balanced and proportionate | Amplified or prolonged |
| Inflammation response | Regulated and controlled | Excessive or persistent |
| CB1 receptor activity | Efficient central pain modulation | Reduced effectiveness |
| CB2 receptor activity | Active inflammation suppression | Impaired immune regulation |
| Overall pain experience | Manageable and context-appropriate | Heightened sensitivity, chronic discomfort |
This comparison makes clear why COVID-19’s disruption of the ECS can have such a significant impact on a patient’s overall pain experience.
This disruption may help explain why many long-COVID patients report pain that feels disproportionate to any visible injury — their internal pain-management system is simply no longer operating as it should.
Conventional Approaches to Post-COVID Pain
Managing pain that lingers after COVID-19 typically begins with treatments already familiar to doctors, adapted carefully for this unique condition.
NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
Medications like ibuprofen and naproxen help reduce inflammation and mild-to-moderate pain. They work best for musculoskeletal complaints such as joint aches or muscle soreness, but long-term use carries risks including stomach irritation and kidney strain, so doctors recommend the lowest effective dose for the shortest necessary period.
Low-Dose Naltrexone (LDN)
Originally developed for addiction treatment, naltrexone at very small doses appears to calm overactive immune responses and reduce central sensitization — a state where the nervous system becomes abnormally sensitive to pain signals. Early clinical observations are encouraging, though large-scale trials are still ongoing.
Gabapentinoids
Drugs like gabapentin and pregabalin target nerve-related pain by reducing excessive electrical signaling in the nervous system. They are particularly useful when patients describe burning, shooting, or tingling sensations, which are hallmarks of neuropathic pain.
Paced Physical Therapy
Rather than pushing through exhaustion, paced therapy introduces gradual, carefully monitored movement. This approach prevents post-exertional symptom worsening — a common problem in long COVID patients — while slowly rebuilding strength and mobility.
CBT-Based Pain Management
Cognitive Behavioral Therapy (CBT) helps patients understand and reframe how the brain processes pain. It does not suggest the pain is imaginary; instead, it builds practical coping strategies that reduce pain’s interference with daily life.
Plant-Derived Compounds and the Endocannabinoid System
The human body contains a built-in regulatory network called the endocannabinoid system (ECS) — a web of receptors, natural chemical messengers, and enzymes that helps control pain, inflammation, mood, and immune responses. Two plant-derived compounds found in cannabis, CBD (cannabidiol) and THC (tetrahydrocannabinol), interact with this system in meaningfully different ways. Understanding how each one works helps explain why researchers are studying them as potential tools for managing chronic pain, including the persistent pain reported by many Long COVID patients.
CBD: Indirect Action, Anti-Inflammatory Promise
CBD does not bind directly to the ECS’s main receptors. Instead, it works indirectly — slowing the breakdown of the body’s own natural pain-calming chemicals and influencing other receptor systems involved in inflammation and nerve signaling. Because of this gentler mechanism, CBD does not produce intoxication.
Research suggests CBD has meaningful anti-inflammatory effects. Studies in animal models and some human trials show it can reduce inflammatory markers and dampen overactive immune responses — both of which are relevant to Long COVID, where inflammation often lingers well beyond the initial infection. CBD products are widely accessible in many countries as supplements, oils, and topical creams, though quality and dosage consistency vary significantly between brands.
THC: Direct Binding, Dual Pain Mechanism
THC works differently. It binds directly to two key ECS receptors: CB1 receptors, concentrated in the brain and spinal cord, and CB2 receptors, found primarily in immune tissues throughout the body. This dual action gives THC a two-pronged approach to pain relief — it can quiet pain signals within the central nervous system while simultaneously reducing peripheral inflammation at the tissue level.
A 2018 meta-analysis published in the Journal of the American Medical Association reviewed 47 randomized controlled trials and found moderate-quality evidence supporting cannabinoids, particularly THC-containing preparations, for treating chronic neuropathic pain — the type caused by nerve damage or dysfunction rather than tissue injury. This finding is directly relevant to Long COVID, where central sensitization (when the brain and spinal cord become abnormally sensitive to pain signals) and neuropathic pain are frequently reported.
Several THC-based medications have received FDA approval. Dronabinol and nabilone are approved for managing chemotherapy-related nausea and appetite loss, demonstrating that pharmaceutical-grade THC can be developed safely within a regulated framework. Researchers are exploring whether similar formulations could address post-COVID pain syndromes.
However, THC carries real limitations. Its psychoactivity — the “high” it produces — makes it unsuitable for many people, particularly those who need to remain fully alert for work or caregiving. Regulatory complexity adds another barrier: THC remains federally controlled in many countries, restricting both patient access and research funding. Critically, Long COVID-specific clinical trials for THC remain limited. Most existing evidence comes from studies on fibromyalgia, multiple sclerosis, or general neuropathic pain — conditions that share features with Long COVID pain but are not identical.
CBD vs. THC: Quick Comparison
The table below provides a side-by-side comparison of CBD and THC across several key features relevant to pain management.
| Feature | CBD | THC |
|---|---|---|
| Mechanism | Indirect ECS modulation | Direct CB1 and CB2 binding |
| Psychoactive | No | Yes |
| Pain Evidence | Emerging; anti-inflammatory | Moderate evidence for neuropathic pain |
| Best Pain Type | Inflammatory, general discomfort | Neuropathic, central sensitization |
| Legal Access | Widely available as supplement | Restricted; varies by jurisdiction |
| Approved Medication | Epidiolex (epilepsy) | Dronabinol, Nabilone |
While both compounds show distinct mechanisms and areas of promise, neither has yet been confirmed as a standard treatment for Long COVID pain.
Both compounds show genuine scientific promise, but neither is a confirmed treatment for Long COVID pain. The existing evidence is encouraging enough to justify continued research, and understanding their distinct mechanisms helps patients and clinicians make more informed, realistic decisions.
Other Emerging Approaches
Beyond the treatments already discussed, researchers are investigating several additional options that show early promise for COVID-related chronic pain.
- Low-level laser therapy (LLLT) uses gentle, non-heating light energy applied directly to painful areas. It appears to reduce inflammation and support nerve repair at the cellular level, though large-scale trials are still ongoing.
- Alpha-lipoic acid is a natural antioxidant — a substance that protects cells from damage — already used in diabetic nerve pain. Some researchers believe it may help calm the nerve inflammation seen in long COVID.
- Low-dose naltrexone (LDN) involves taking tiny amounts of a medication normally used for addiction treatment. At micro-doses, it appears to quiet overactive immune cells in the nervous system called microglia, potentially reducing pain signals.
None of these approaches are yet standard treatments, but they represent an actively growing area of research that may eventually offer additional relief options for long COVID patients.
Conclusion
COVID-19 does more than cause a temporary illness — for many people, it triggers lasting pain that lingers long after the infection clears. This happens through inflammation, nerve damage, immune disruption, and changes in how the brain processes pain signals. Understanding these mechanisms helps explain why chronic pain after COVID-19 is real, measurable, and deserving of serious medical attention. Researchers are actively working to identify better treatments and uncover why some people are more vulnerable than others. If you are living with post-COVID pain, know that the science is catching up, and support is available.